레지오넬라균 검사 시장 보고서 : 용도별, 최종사용자별, 지역별(2026-2034년)

The global legionella testing market size reached USD 390.9 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 694.4 Million by 2034, exhibiting a growth rate (CAGR) of 6.40% during 2026-2034. The increasing number of individuals who have diabetes, kidney disease, human immunodeficiency virus (HIV), cancer, or other chronic illnesses, are at risk of hospitalization, which is stimulating the market growth.

LEGIONELLA TESTING MARKET ANALYSIS:

• Major Market Drivers: The increasing demand for legionella testing in workplace buildings is one of the primary drivers bolstering the market. Besides this, the launch of favorable policies by health agencies to develop an effective water safety plan (WSP) is also acting as another significant growth-inducing factor.
• Key Market Trends: Recent clinical trials on treatment and diagnostic strategies for adult patients with community-acquired pneumonia are positively influencing the market. Moreover, extensive investments in R&D activities are further stimulating the market growth.
• Competitive Landscape: Some of the prominent players in the global market include Abbott Laboratories, Bio-Rad Laboratories, Inc., Eiken Chemical Co., Ltd., IDEXX, Pro-Lab Diagnostics, Qiagen N.V, QuidelOrtho Corporation, and Thermo Fisher Scientific Inc., among many others.
• Geographical Trends: Europe exhibits a clear dominance in the market. This can be attributed to the growing number of public health campaigns and educational programs, which is escalating the demand for legionella testing services. Moreover, the increasing focus among key players on maintaining high standards of patient care and safety is bolstering the regional market.
• Challenges and Opportunities: The complexities and high cost of legionella testing procedures are among the primary factors hindering the market growth. However, the introduction of simpler and more cost-effective testing kits that can help in making legionella testing more accessible is expected to fuel the market over the forecasted period.

LEGIONELLA TESTING MARKET TRENDS:

Rising Prevalence of Legionellosis

The rising incidences related to Legionellosis disease, which is a pneumonia-like illness, usually caused by a bacterium that varies in severity from mild to severe illness and sometimes fatal form of pneumonia, are propelling the market. For example, in September 2023, a total of 166 cases of legionellosis, including 23 deaths, were reported from Poland. Additionally, in May 2023, the Lithuanian National Public Health Center reported the investigation of an unexpected number of cases of Legionnaires' disease in the Kaunas district of Lithuania, Europe. In line with this, Legionella bacteria was found in water samples from the buildings where the cases resided. Furthermore, the proliferation of Legionella-causing bacteria that are commonly found in several artificial and natural aquatic environments, such as respiratory therapy equipment, fountains, misting devices, cooling towers, spa pools, and water systems in hotels, homes, factories, etc., is also catalyzing the legionella testing market outlook. For instance, in July 2022, the Pennsylvania Department of Health received two reports of laboratory-confirmed Legionnaires disease in patients who received lung transplants from the same donor at a single Pennsylvania hospital. The donor's cause of death was freshwater drowning in a river, raising suspicion of potential donor-derived transmission because Legionella bacteria naturally live in fresh water. As a result, health agencies in various countries are launching an effective water safety plan (WSP) to reduce the proliferation of Legionella in the water. Some of the common rules and regulations pertinent to the disease include the Surface Water Treatment Rule (SWTR) and the Safe Drinking Water Act (SDWA).

Various Technological Advancements

The increasing number of clinical trials on diagnostic and treatment strategies for patients with community-acquired pneumonia is strengthening the market. Key players in the healthcare industry are focusing on introducing novel molecular diagnostics and rapid test methods, as they offer more accurate and quicker testing outcomes, thereby improving the efficiency of legionella testing and control strategies. For example, in December 2023, one of the diversified biotechnology companies, CCM Biosciences (CCM Bio), launched its business unit, CCM 5Prime Sciences (5Prime), focused on the globally commercialized and multiple patent-protected compositions for next-generation DNA sequencing and molecular diagnostics. Apart from this, sensitive and rapid PCR-based methods are gaining immense traction as alternatives to the conventional culture system for the detection of slow-growing bacteria, such as Legionella spp. They use specific fluorescent probes that allow them to detect bacteria in water samples. Prominent brands, including Biopremier, offer simple, reliable, and rapid procedures, including real-time PCR detection test kits, to detect Legionella spp. Moreover, the widespread integration of technologies, such as artificial intelligence (AI), to identify and predict potential legionella outbreaks by analyzing data trends, including flow rates and water temperature, is elevating the legionella testing market share. For example, in May 2024, the Dubai Central Laboratory introduced a new artificial intelligence (AI) technology to seamlessly detect Legionella, a bacterium that causes acute respiratory infections.

Growing Regulatory Standards

Regulatory and government bodies across the globe are implementing stricter drinking water standards and regulations to control legionella outbreaks, especially in hotels, healthcare facilities, public buildings, etc. These regulations mandate regular risk and water testing assessments to ensure public safety, thereby escalating the demand for legionella testing services. For example, in April 2024, the U.S. Environmental Protection Agency (EPA) released the first-ever National Primary Drinking Water Regulation for certain per- and polyfluoroalkyl substances (PFAS), also known as 'forever chemicals.' Besides this, for drinking water, the World Health Organization (WHO) suggests that Legionella bacteria should be absent in water utilized for human consumption. Numerous guidelines, often set by local authorities or industry standards, indicate acceptable levels and testing protocols. They generally involve implementing measures and monitoring Legionella counts to ensure they remain below certain thresholds to reduce associated health risks. For instance, in the United States, the Centers for Disease Control and Prevention (CDC) provides guidance on Legionella testing and management for several water systems. Furthermore, other organizations, such as the American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE), provide recommendations for action levels related to this infection. Consequently, facility managers are taking corrective actions to protect the health of occupants. Some of the leaders in providing innovative solutions, including IWC Innovations, offer expertise in Legionella risk mitigation, focusing on investigation, detection, prevention, and remediation of the disease.

LEGIONELLA TESTING MARKET SEGMENTATION:

Breakup by Application:

• Water Testing
  • Microbial Culture
  • DFA Stain
  • PCR
  • Others
• IVD Testing
  • Blood Culture
  • Urine Antigen Test
  • DFA Stain
  • PCR
  • Others

Currently, water testing holds the majority of the market share

The increasing need for comprehensive and regular water quality assessments in several facilities, including hotels, commercial buildings, hospitals, residential complexes, etc., where stagnant water can become a breeding ground for legionella bacteria is driving the growth in this segmentation. Moreover, the widespread adoption of water testing methods that can allow for timely intervention measures is also acting as another significant growth-inducing factor. For example, in May 2022, ChemREADY, one of the manufacturers of water and wastewater treatment chemicals, introduced its Legionella testing services and product line to mitigate water-borne infection in building water systems. Besides this, the growing number of educational and training programs for building owners, employees, facility managers, etc., is creating lucrative opportunities for water consulting and testing services. For instance, in June 2023, Consulting and Testing Services, Inc. (CTSI), one of the prominent providers of industrial hygiene, offered infection control and environmental testing services in New Jersey to identify sources of Legionella bacteria to support water management programs.

Breakup by End User:

• Diagnostic Laboratories
• Hospital and Clinics

Among these, diagnostic laboratories currently account for the largest market share

The increasing requirement for timely and accurate results that are crucial for timely interventions is augmenting the market across this segment. For instance, diagnostic labs, including LabCorp and Quest Diagnostics, offer comprehensive legionella testing services, ranging from collecting water samples from various types of facilities to analyzing them using novel methods, such as polymerase chain reaction (PCR), culture techniques, serology, etc. Additionally, continuous collaborations and partnerships are expected to fuel the segment's growth in the coming years. For instance, in December 2021, Pace Analytical Services, one of the companies that offer environmental sampling and analytical support services to detect trace-level inorganic and organic contaminants in water, soil, air, etc., acquired Special Pathogens Laboratory to strengthen testing capabilities for Legionella disease.

Breakup by Region:

• Europe
  • Italy
  • Germany
  • France
  • Spain
  • United Kingdom
  • Russia
  • Others
• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • Australia
  • South Korea
  • Indonesia
  • Singapore
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

According to the legionella testing industry analysis, Europe exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Europe (Italy, Germany, France, Spain, the United Kingdom, Russia, and others); North America (the United States and Canada); Asia Pacific (China, Japan, Australia, South Korea, Indonesia, Singapore, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.

The rising prevalence of infections, such as Legionella, which can lead to severe pneumonia, is bolstering the market across Europe. For example, as per the data published by the National Center for Biotechnology Information (NCBI) in October 2023, the European Centre for Disease Prevention and Control (ECDC) reported a rise in Legionella outbreaks and confirmed cases across its member states. Similarly, in 2022, around 194 deaths were confirmed from Legionnaires' disease in France. Apart from this, the implementation of stringent regulations by government bodies that mandate regular and comprehensive water testing in public buildings and facilities that are at high risk of legionella contamination is also acting as another significant growth-inducing factor. For instance, guidelines are outlined by the German Technical and Scientific Association for Gas and Water (DVGW) that require all healthcare facilities to conduct legionella testing at least bi-annually. Additionally, the rising adoption of advanced testing technologies, such as quantitative polymerase chain reaction (qPCR) methods, is expected to bolster the regional market. For example, various companies like, Eurofins Scientific and SGS SA, are providing cutting-edge testing services that meet the escalating demand for accuracy and efficiency in legionella detection across Europe.

COMPETITIVE LANDSCAPE:

The legionella testing market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Eiken Chemical Co., Ltd.
• IDEXX
• Pro-Lab Diagnostics
• Qiagen N.V
• QuidelOrtho Corporation
• Thermo Fisher Scientific Inc.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Legionella Testing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Water Testing
  • 6.1.1 Market Trends
  • 6.1.2 Market Breakup by Type
    • 6.1.2.1 Microbial Culture
    • 6.1.2.2 DFA Stain
    • 6.1.2.3 PCR
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 IVD Testing
  • 6.2.1 Market Trends
  • 6.2.2 Market Breakup by Type
    • 6.2.2.1 Blood Culture
    • 6.2.2.2 Urine Antigen Test
    • 6.2.2.3 DFA Stain
    • 6.2.2.4 PCR
    • 6.2.2.5 Others
  • 6.2.3 Market Forecast

7 Market Breakup by End User

• 7.1 Diagnostic Laboratories
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hospital and Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 Europe
  • 8.1.1 Italy
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Germany
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
  • 8.1.3 France
    • 8.1.3.1 Market Trends
    • 8.1.3.2 Market Forecast
  • 8.1.4 Spain
    • 8.1.4.1 Market Trends
    • 8.1.4.2 Market Forecast
  • 8.1.5 United Kingdom
    • 8.1.5.1 Market Trends
    • 8.1.5.2 Market Forecast
  • 8.1.6 Russia
    • 8.1.6.1 Market Trends
    • 8.1.6.2 Market Forecast
  • 8.1.7 Others
    • 8.1.7.1 Market Trends
    • 8.1.7.2 Market Forecast
• 8.2 North America
  • 8.2.1 United States
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Canada
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 China
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 Japan
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 Australia
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 South Korea
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Indonesia
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Singapore
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weakness
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porter's Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Bio-Rad Laboratories, Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Eiken Chemical Co., Ltd.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
  • 13.3.4 IDEXX
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Pro-Lab Diagnostics
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Qiagen N.V
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 QuidelOrtho Corporation
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 inancials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Thermo Fisher Scientific Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis